Campbell & Co Investment Adviser’s Crinetics Pharmaceuticals CRNX Stock Holding History

Campbell & Co Investment Adviser’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.12M	Sell	29,957 -53,660	-64%	-$1.99M	0.06%	507
2026 Q1	$3.04M	Buy	+83,617	New	+$3.73M	0.17%	170
2025 Q2	–	Sell	-7,048	Closed	-$236K	–	1182
2025 Q1	$236K	Buy	+7,048	New	+$263K	0.02%	904
2023 Q4	–	Sell	-63,917	Closed	-$1.9M	–	1133
2023 Q3	$1.9M	Buy	63,917 +42,323	+196%	+$872K	0.23%	102
2023 Q2	$389K	Buy	+21,594	New	+$431K	0.07%	549

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Campbell & Co Investment Adviser's CRNX Position: Q2 2026 in Review

Campbell & Co Investment Adviser reduced its Crinetics Pharmaceuticals (CRNX) stake by 64% in Q2 2026, selling an estimated $1.99M and leaving 29,957 shares worth $1.12M. The position accounts for 0.06% of the portfolio, ranked #507.

Campbell & Co Investment Adviser first reported a position in CRNX in Q2 2023 and has held it in 5 quarters since. The position peaked at $3.04M in Q1 2026. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

Campbell & Co Investment Adviser held 29,957 shares of Crinetics Pharmaceuticals worth $1.12M as of Q2 2026.
Campbell & Co Investment Adviser sold 53,660 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $1.99M.
Crinetics Pharmaceuticals made up 0.06% of Campbell & Co Investment Adviser's portfolio in Q2 2026, its #507 holding.
Campbell & Co Investment Adviser first reported a position in Crinetics Pharmaceuticals in Q2 2023 and has held it in 5 quarters since.
Campbell & Co Investment Adviser's Crinetics Pharmaceuticals position peaked at $3.04M in Q1 2026.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Campbell & Co Investment Adviser's 13F filing for Q2 2026, filed 3 Aug 2026.